Obesity - sibutramine (replaced by CG43)

Summary

This guidance is obsolete and has been replaced by CG43 Obesity.

Documents

For healthcare professionals

• TA31 Obesity - sibutramine: Summary
• TA31 Obesity - sibutramine: Guidance
• TA31 Obesity - sibutramine: Guidance (html)

For patients, carers and the public

• TA31 Obesity - sibutramine: Information for the public
• TA31 Obesity - sibutramine: Information for the public (html)

Background information

• A systematic review of the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity
• Review of NICE Technology Appraisal Guidance Nos 22, orlistat and 31 sibutramine for the treatment of obesity in adults
• Review of NICE Technology Appraisal Guidance Nos 22, orlistat and 31 sibutramine for the treatment of obesity in adults
• 2001/32 NICE issues guidance on sibutramine for obesity

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• None found